Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX
Iizuka, A.; Kuwashima, M.; Nagao, T.
Nihon Ketsueki Gakkai Zasshi Journal of Japan Haematological Society 45(5): 987-992
1982
ISSN/ISBN: 0001-5806 PMID: 6818811 Document Number: 185584
Document emailed within 1 workday
Related Documents
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Lottenberg, R.; Kentro, T.B.; Kitchens, C.S. 1987: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Archives of Internal Medicine 147(6): 1077-1081
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Brakman, G.G. 1993: The occurrence of immunological tolerance to inhibitors of factors VIIi and IX in hemophilia patients Gematologiia i Transfuziologiia 38(2): 18-20
Lopaciuk, S.; Ziemski, J.M. 1979: Treatment of patients with hemophilia a having antibodies to factor VIIi Acta Haematologica Polonica 10(2): 115-122
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Mauser-Bunschoten, E.P.; Damen, M.; Reesink, H.W.; Roosendaal, G.; Chamuleau, R.A.; van den Berg, H.M. 1996: Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C Annals of Internal Medicine 125(4): 297-299
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Kätzel, R.; Kubel, M.; Scheel, H.; Wegner, H. 1978: Results of in vivo analysis of injected fibrinogen degradation products and factor VIIi in patients with hemophilia a Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 33(15): 525-529
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61
Takase, T.; Nishino, M.; Yasui, M.; Shima, M.; Yoshikawa, N.; Fukui, H. 1985: Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia a and von Willebrand's disease Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 48(7): 1571-1578
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247